Biopolym. Cell. 2000; 16(3):186-194.
http://dx.doi.org/10.7124/bc.000565
Reviews
Immunogenetics aspects of Down syndrome
1Zastavna D. V., 1Terpyliak O. I., 1Hnateiko O. Z.
  1. Institute of Hereditary Pathology MAS of Ukraine
    31a, Lysenko Str., Lviv, Ukraine, 79008

Abstract

The review on immunogenetic aspects of the Down syndrome is presented. Since immunological status of an organism and correspondingly predisposition to any disease are determined by the function of major histocompatibility complex antigens (HLA-antigens) the present paper is focused on the peculiarities of HLA-antigens distribution at the Down syndrome formation as well as other regulatory factors, in particular, interferon. A possible involvement of autoimmune thyroiditis as a risk factor of this pathology for offspring is also disscussed.
Full text: (PDF, in Ukrainian)

References

[1] Kozlova SI, Semenova E, Demikova NS, Blinnikova OG. Hereditary syndromes, medical and genetic counseling. M.: Meditsina, 1987: 320.
[2] Hermon M, Cairns N, Egly JM, Fery A, Labudova O, Lubec G. Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down Syndrome and Alzheimer's disease. Neurosci Lett. 1998;251(1):45-8.
[3] Chang YC, Huang CC, Huang SC. Volumetric neuroimaging in children with neurodevelopmental disorders--mapping the brain and behavior. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998;39(5):285-92.
[4] Royston MC, Mann D, Pickering-Brown S, Owen F, Perry R, Ragbavan R, Khin-Nu C, Tyner S, Day K, Crook R, Hardy J, Roberts GW. ApoE2 allele, Down's syndrome, and dementia. Ann N Y Acad Sci. 1996;777:255-9.
[5] Sawa A, Oyama F, Cairns NJ, Amano N, Matsushita M. Aberrant expression of bcl-2 gene family in Down's syndrome brains. Brain Res Mol Brain Res. 1997;48(1):53-9.
[6] Sekijima Y, Ikeda S, Tokuda T, Satoh S, Hidaka H, Hidaka E, Ishikawa M, Yanagisawa N. Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. Eur Neurol. 1998;39(4):234-7.
[7] van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, K?yc? S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 1998;279(5348):242-7.
[8] Digilio MC, Marino B, Canepa SA, Borzaga U, Giannotti A, Dallapiccola B. Congenital heart defect in sibs with discordant karyotypes. Am J Med Genet. 1998;80(2):169-72.
[9] Haw CM, Barnes TR, Clark K, Crichton P, Kohen D. Movement disorder in Down's syndrome: a possible marker of the severity of mental handicap. Mov Disord. 1996;11(4):395-403.
[10] K?ll?n B, Mastroiacovo P, Robert E. Major congenital malformations in Down syndrome. Am J Med Genet. 1996;65(2):160-6.
[11] Stoll C, Alembik Y, Dott B, Roth MP. Study of Down syndrome in 238,942 consecutive births. Ann Genet. 1998;41(1):44-51.
[12] * Sustrova M., Sarikova V. Downov syndrom-dosledky zvy-senej expresie genov 21. chromozomu na funkciu imunitneho a nervoveho systemu. Bratisl. Lekarske Listy. 1997. 98, N 4: 221-228.
[13] Torfs CP, Christianson RE. Anomalies in Down syndrome individuals in a large population-based registry. Am J Med Genet. 1998;77(5):431-8.
[14] Chrobok V, Sim?kov? E. Temporal bone findings in trisomy 18 and 21 syndromes. Eur Arch Otorhinolaryngol. 1997;254(1):15-8.
[15] Ludwig M, Busch LC, Winking H. The embryonic development of sensory organs and the skull in the trisomy 16 mouse, an animal model for Down's syndrome. Ann Anat. 1997;179(6):525-33.
[16] Decoq P, Vinckier F. Down syndrome: 1. Medical aspects. Rev Belge Med Dent (1984). 1995;50(3):43-52.
[17] Failla P, Ruberto C, Pagano MC, Lombardo M, Bottaro G, Perichon B, Krishnamoorthy R, Romano C, Ragusa A. Celiac disease in Down's syndrome with HLA serological and molecular studies. J Pediatr Gastroenterol Nutr. 1996;23(3):303-6.
[18] Amiel A, Avivi L, Gaber E, Fejgin MD. Asynchronous replication of allelic loci in Down syndrome. Eur J Hum Genet. 1998;6(4):359-64.
[19] Satge D. A decreased incidence of neuroblastomas in Down's syndrome and overproduction of S-100 b protein. Med Hypotheses. 1996;46(4):393-9.
[20] Schmidt S. S100B: pathogenetic and pathophysiologic significance in neurology. Nervenarzt. 1998;69(8):639-46.
[21] Yamakawa K, Huot YK, Haendelt MA, Hubert R, Chen XN, Lyons GE, Korenberg JR. DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. Hum Mol Genet. 1998;7(2):227-37.
[22] Fuentes JJ, Pritchard MA, Estivill X. Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics. 1997;44(3):358-61.
[23] Guipponi M, Scott HS, Chen H, Schebesta A, Rossier C, Antonarakis SE. Two isoforms of a human intersectin (ITSN) protein are produced by brain-specific alternative splicing in a stop codon. Genomics. 1998;53(3):369-76.
[24] Tsukahara F, Urakawa I, Hattori M, Hirai M, Ohba K, Yoshioka T, Sakaki Y, Muraki T. Molecular characterization of the mouse mtprd gene, a homologue of human TPRD: unique gene expression suggesting its critical role in the pathophysiology of Down syndrome. J Biochem. 1998;123(6):1055-63.
[25] Galdzicki Z, Coan EJ, Rapoport SI, Stoll J. Increased expression of voltage-activated calcium channels in cultured hippocampal neurons from mouse trisomy 16, a model for Down syndrome. Brain Res Mol Brain Res. 1998;56(1-2):200-6.
[26] Groet J, Ives JH, South AP, Baptista PR, Jones TA, Yaspo ML, Lehrach H, Potier MC, Van Broeckhoven C, Nizeti? D. Bacterial contig map of the 21q11 region associated with Alzheimer's disease and abnormal myelopoiesis in Down syndrome. Genome Res. 1998;8(4):385-98.
[27] Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol. 1998;43(3):380-3.
[28] Lambert JC, P?rez-Tur J, Dupire MJ, Delacourte A, Frigard B, Chartier-Harlin MC. Analysis of the APOE alleles impact in Down's syndrome. Neurosci Lett. 1996;220(1):57-60.
[29] Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett. 1998;241(1):13-6.
[30] Tyrrell J, Cosgrave M, Hawi Z, McPherson J, O'Brien C, McCalvert J, McLaughlin M, Lawlor B, Gill M. A protective effect of apolipoprotein E e2 allele on dementia in Down's syndrome. Biol Psychiatry. 1998;43(6):397-400.
[31] Del Bo R, Comi GP, Bresolin N, Castelli E, Conti E, Degiuli A, Ausenda CD, Scarlato G. The apolipoprotein E epsilon4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. J Neurol Sci. 1997;145(1):87-91.
[32] Avramopoulos D, Mikkelsen M, Vassilopoulos D, Grigoriadou M, Petersen MB. Apolipoprotein E allele distribution in parents of Down's syndrome children. Lancet. 1996;347(9005):862-5.
[33] Brodsky G, Barnes T, Bleskan J, Becker L, Cox M, Patterson D. The human GARS-AIRS-GART gene encodes two proteins which are differentially expressed during human brain development and temporally overexpressed in cerebellum of individuals with Down syndrome. Hum Mol Genet. 1997;6(12):2043-50.
[34] Kempski HM, Chessells JM, Reeves BR. Deletions of chromosome 21 restricted to the leukemic cells of children with Down syndrome and leukemia. Leukemia. 1997;11(11):1973-7.
[35] Satg? D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. Am J Med Genet. 1998;78(3):207-16.
[36] Ives JH, Dagna-Bricarelli F, Basso G, Antonarakis SE, Jee R, Cotter F, Nizeti? D. Increased levels of a chromosome 21-encoded tumour invasion and metastasis factor (TIAM1) mRNA in bone marrow of Down syndrome children during the acute phase of AML(M7). Genes Chromosomes Cancer. 1998;23(1):61-6.
[37] Mertens AC, Wen W, Davies SM, Steinbuch M, Buckley JD, Potter JD, Robison LL. Congenital abnormalities in children with acute leukemia: a report from the Children's Cancer Group. J Pediatr. 1998;133(5):617-23.
[38] Litz CE, Davies S, Brunning RD, Kueck B, Parkin JL, Gajl Peczalska K, Arthur DC. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia. 1995;9(9):1432-9.
[39] Kempski HM, Craze JL, Chessells JM, Reeves BR. Cryptic deletions and inversions of chromosome 21 in a phenotypically normal infant with transient abnormal myelopoiesis: a molecular cytogenetic study. Br J Haematol. 1998;103(2):473-9.
[40] Cavani S, Perfumo C, Argusti A, Pierluigi M, Perroni L, Schmiegelow K, Petersen MB, Cotter FE, Strigini P, Dagna-Bricarelli F, Nizeti? D. Cytogenetic and molecular study of 32 Down syndrome families: potential leukaemia predisposing role of the most proximal segment of chromosome 21q. Br J Haematol. 1998;103(1):213-6.
[41] Finette BA, Rood B, Poseno T, Vacek P, Pueschel S, Homans AC. Atypical background somatic mutant frequencies at the HPRT locus in children and adults with Down syndrome. Mutat Res. 1998;403(1-2):35-43.
[42] Casorzo L, Fessia L, Sapino A, Ponzio G, Bussolati G. Extraskeletal Ewing's tumor with translocation t(11;22) in a patient with Down syndrome. Cancer Genet Cytogenet. 1989;37(1):79-84.
[43] Maroun LE. Interferon action and chromosome 21 trisomy (Down syndrome): 15 years later. J Theor Biol. 1996;181(1):41-6.
[44] Gerdes AM, H?rder M, Petersen PH, Bonnevie-Nielsen V. Effect of increased gene dosage expression on the alpha-interferon receptors in Down's syndrome. Biochim Biophys Acta. 1993;1181(2):135-40.
[45] Gerdes AM, H?rder M, Bonnevie-Nielsen V. Increased IFN-alpha-induced sensitivity but reduced reactivity of 2',5'-oligoadenylate synthetase (2,5AS) in trisomy 21 blood lymphocytes. Clin Exp Immunol. 1993;93(1):93-6.
[46] Pash J, Popescu N, Matocha M, Rapoport S, Bustin M. Chromosomal protein HMG-14 gene maps to the Down syndrome region of human chromosome 21 and is overexpressed in mouse trisomy 16. Proc Natl Acad Sci U S A. 1990;87(10):3836-40.
[47] Cox DR, Epstein LB, Epstein CJ. Genes coding for sensitivity to interferon (IfRec) and soluble superoxide dismutase (SOD-1) are linked in mouse and man and map to mouse chromosome 16. Proc Natl Acad Sci U S A. 1980;77(4):2168-72.
[48] Druzhyna N, Nair RG, LeDoux SP, Wilson GL. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Mutat Res. 1998;409(2):81-9.
[49] Epstein LB, Epstein CJ. T-lymphocyte function and sensitivity to interferon in trisomy 21. Cell Immunol. 1980;51(2):303-18.
[50] Zihni L. Down's syndrome, interferon sensitivity and the development of leukaemia. Leuk Res. 1994;18(1):1-6.
[51] Egeo A, Mazzocco M, Arrigo P, Vidal-Taboada JM, Oliva R, Pirola B, Giglio S, Rasore-Quartino A, Scartezzini P. Identification and characterization of a new human gene encoding a small protein with high homology to the proline-rich region of the SH3BGR gene. Biochem Biophys Res Commun. 1998;247(2):302-6.
[52] Gosset P, Ghezala GA, Korn B, Yaspo ML, Poutska A, Lehrach H, Sinet PM, Cr?au N. A new inward rectifier potassium channel gene (KCNJ15) localized on chromosome 21 in the Down syndrome chromosome region 1 (DCR1). Genomics. 1997;44(2):237-41.
[53] Paoloni-Giacobino A, Chen H, Antonarakis SE. Cloning of a novel human neural cell adhesion molecule gene (NCAM2) that maps to chromosome region 21q21 and is potentially involved in Down syndrome. Genomics. 1997;43(1):43-51.
[54] Khaitov RM, Molochko VT, Alekseev LYa. Immuno-genetics and immunology of resistance to infections. Tashkent: Publishing house Ibn Sina, 1991. 246 p.
[55] Dausset J, Contu L. Is the MHC a general self-recognition system playing a major unifying role in an organism? Hum Immunol. 1980;1(1):5-17.
[56] Alekseev LP, Khaitov RM. Using molecular genetic typing of HLA-class II genes in clinical transplantation. International Zh immunorehabilitation. 1997; (6): 8-19.
[57] Powis SH, Tork SS., Bodmer J. HLA-system and diseases. J Immunogenet. 1993; 37: 373-380.
[58] Alekseev LL. The biological role of HLA. Imunologiia. 1985;(3):6: 6-10.
[59] Usichenko IT. I HLA class system and modern methods of typing. Zh. Akad Med Nauk Ukr. 1998; 4(3): 462-476.
[60] SHabalin VN, Serova LD. Modern concepts of human blood antigens. Ross Vest Perinatologii i Pediatrii. 1996; 6: 35-42.
[61] Medunitsin NV, Alekseev LP. HLA antigenes systems . M.: Meditsina, 1987: 175.
[62] Draniik GM. Structure and function of histocompatibility antigens systems HLA. Lab. DIagn. 1997. (2): 19-27.
[63] Zaretskaya YuM. Clinical immunogenetics. M.: Meditsina, 1983: 208.
[64] Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today. 1993;14(7):349-52.
[65] Mange AP, Mange EJ. Genetics: Human Aspects. Sunderland: Sinauer Assoc. Inc., 1990. 2nd ed: 591.
[66] Kong YC, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, H?mmerling GJ, David CS. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med. 1996;184(3):1167-72.
[67] Bouchou K, Andr? M, Cathebras P, Cauhape P, Aumaitre O, Rousset H. Thyroid pathology and multiple autoimmune syndrome: clinical and immunogenetic aspect, apropos of 11 cases. Rev Med Interne. 1993;14(10):991.
[68] Spina MP, Santi G, Dugnani DA, Cerri A, Santagati G, Far? M, Mercuriali F. Hashimoto's thyroiditis and HLA in Caucasian Italians. Minerva Endocrinol. 1993;18(2):77-81.
[69] Shi Y, Zou M, Robb D, Farid NR. Typing for major histocompatibility complex class II antigens in thyroid tissue blocks: association of Hashimoto's thyroiditis with HLA-DQA0301 and DQB0201 alleles. J Clin Endocrinol Metab. 1992;75(3):943-6.
[70] Chikuba N, Akazawa S, Yamaguchi Y, Kawasaki E, Takino H, Yoshimoto M, Ohe N, Yamashita K, Yano A, Nagataki S. Immunogenetic heterogeneity in type 1 (insulin-dependent) diabetes among Japanese--class II antigen and autoimmune thyroid disease. Diabetes Res Clin Pract. 1995;27(1):31-7.
[71] Tamai H, Kimura A. DNA typing of HLA antigen in patients with autoimmune thyroid disease using the PCR-SSOP method. Nihon Rinsho. 1994;52(4):1018-23.
[72] Mangklabruks A, Cox N, DeGroot LJ. Genetic factors in autoimmune thyroid disease analyzed by restriction fragment length polymorphisms of candidate genes. J Clin Endocrinol Metab. 1991;73(2):236-44.
[73] Tandon N, Zhang L, Weetman AP. HLA associations with Hashimoto's thyroiditis. Clin Endocrinol (Oxf). 1991;34(5):383-6.
[74] Roman SH, Greenberg D, Rubinstein P, Wallenstein S, Davies TF. Genetics of autoimmune thyroid disease: lack of evidence for linkage to HLA within families. J Clin Endocrinol Metab. 1992;74(3):496-503.
[75] Inoue D, Sato K, Sugawa H, Akamizu T, Maeda M, Inoko H, Tsuji K, Mori T. Apparent genetic difference between hypothyroid patients with blocking-type thyrotropin receptor antibody and those without, as shown by restriction fragment length polymorphism analyses of HLA-DP loci. J Clin Endocrinol Metab. 1993;77(3):606-10.
[76] Inoue D, Sato K, Maeda M, Inoko H, Tsuji K, Mori T, Imura H. Genetic differences shown by HLA typing among Japanese patients with euthyroid Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis: genetic characteristics of euthyroid Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1991;34(1):57-62.
[77] Fu Y, Yan G, Shi L, Faustman D. Antigen processing and autoimmunity. Evaluation of mRNA abundance and function of HLA-linked genes. Ann N Y Acad Sci. 1998;842:138-55.
[78] Chuang LM, Wu HP, Chang CC, Tsai WY, Chang HM, Tai TY, Lin BJ. HLA DRB1/DQA1/DQB1 haplotype determines thyroid autoimmunity in patients with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf). 1996;45(5):631-6.
[79] Yamato E, Ikegami H, Kawaguchi Y, Fujisawa T, Hamada Y, Ueda H, Shintani M, Ogihara T. Insulin-dependent diabetes mellitus associated with autoimmune thyroiditis and rheumatoid arthritis. Am J Med Sci. 1997;313(1):64-6.
[80] Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U, Schleusener H, Usadel KH. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab. 1995;80(7):2112-7.
[81] Donner H, Braun J, Seidl C, Rau H, Finke R, Ventz M, Walfish PG, Usadel KH, Badenhoop K. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab. 1997;82(12):4130-2.
[82] Dorman J, Kramer MK, O'Lear LA, Burke JP, McCanlies E, McCarthy BJ, Trucco M, Swan JS, Steenkiste AR, Koehler AN, Foley TP. Molecular epidemiology of autoimmune thyroid disease. Gac Med Mex. 1997;133 Suppl 1:97-103.
[83] McCanlies E, O'Leary LA, Foley TP, Kramer MK, Burke JP, Libman A, Swan JS, Steenkiste AR, Mccarthy BJ, Trucco M, Dorman JS. Hashimoto's thyroiditis and insulin-dependent diabetes mellitus: differences among individuals with and without abnormal thyroid function. J Clin Endocrinol Metab. 1998;83(5):1548-51.
[84] Eber O, Langsteger W. Clinical aspects of autoimmune thyroid diseases. Acta Med Austriaca. 1994;21(1):1-7.
[85] Yang D, Gao Y, Li C. Expression of thyrotropin receptor gene in autoimmune thyroid disease and the relation to expression of HLA genes. Zhonghua Yi Xue Za Zhi. 1996;76(10):753-5.
[86] Paschke R, Schuppert F, Taton M, Velu T. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J Endocrinol. 1994;141(2):309-15.
[87] de la Vega JR, Vilaplana JC, Biro A, Hammond L, Bottazzo GF, Mirakian R. IL-10 expression in thyroid glands: protective or harmful role against thyroid autoimmunity? Clin Exp Immunol. 1998;113(1):126-35.
[88] Morris A. What is the relevance of the various immunomodulatory effects of interferons? Ann Inst Pasteur Immunol. 1985;136D(1):79-81.
[89] Basham TY, Smith WK, Merigan TC. Interferon enhances antibody-dependent cellular cytotoxicity when suboptimal concentrations of antibody are used. Cell Immunol. 1984;88(2):393-400.
[90] Dayton ET, Matsumoto-Kobayashi M, Perussia B, Trinchieri G. Role of immune interferon in the monocytic differentiation of human promyelocytic cell lines induced by leukocyte conditioned medium. Blood. 1985;66(3):583-94.
[91] Drannik GN, Dzik GM. Human blood Genetic system and disease. K.: Zdorov'ya, 1989: 197.
[92] Hurme M, Sihvola M. Cytokine modulation of HLA-DR expression on proliferating cord blood T cells. Immunol Lett. 1989;20(3):217-22.
[93] Aym? S, Mercier P, Dallest R, Mattei JF. HLA and trisomy 21. Confirmation of a trend of restricted HLA heterogeneity in parents of Down syndrome children. Am J Hum Genet. 1984;36(2):405-12.
[94] Castro M, Crin? A, Papadatou B, Purpura M, Giannotti A, Ferretti F, Colistro F, Mottola L, Digilio MC, Lucidi V, et al. Down's syndrome and celiac disease: the prevalence of high IgA-antigliadin antibodies and HLA-DR and DQ antigens in trisomy 21. J Pediatr Gastroenterol Nutr. 1993;16(3):265-8.
[95] S?hoel DC, Johannessen AC, Kristoffersen T, Nilsen R. Expression of HLA class II antigens in marginal periodontitis of patients with Down's syndrome. Eur J Oral Sci. 1995;103(4):207-13.
[96] Tambyah PA, Cheah JS. Hyperthyroidism and Down syndrome. Ann Acad Med Singapore. 1993;22(4):603-5.
[97] Nicholson LB, Wong FS, Ewins DL, Butler J, Holland A, Demaine AG, McGregor AM. Susceptibility to autoimmune thyroiditis in Down's syndrome is associated with the major histocompatibility class II DQA 0301 allele. Clin Endocrinol (Oxf). 1994;41(3):381-3.
[98] Iughetti L, Cassaro F, De Fanti A, Vanelli M, Ottaviani A. Autoimmune endocrinopathies and Down's syndrome: a case report. Pediatr Med Chir. 1993;15(2):207-8.